Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $19.6800 (4.57%) ($18.6100 - $19.8000) on Thu. Sep. 20, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.92% (three month average) | RSI | 25 | Latest Price | $19.6800(4.57%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -2.5% a day on average for past five trading days. | Weekly Trend | ADMS declines -7.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(21%) IBB(19%) ONLN(19%) XOP(18%) IWM(16%) | Factors Impacting ADMS price | ADMS will decline at least -1.46% in a week (0% probabilities). VIXM(-10%) UNG(-10%) BNDX(-9%) UUP(-8%) VXX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.46% (StdDev 2.92%) | Hourly BBV | 0 () | Intraday Trend | 4% | | | |
|
1 - 5 Day Possible Target | $8.63(-56.15%) | Resistance Level | $21.81 | 5 Day Moving Average | $19.78(-0.51%) | 10 Day Moving Average | $21.09(-6.69%) | 20 Day Moving Average | $21.81(-9.77%) | To recent high | -28.1% | To recent low | 5.4% | Market Cap | $557m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |